Efficacy of 3,5-dibromo-L-phenylalanine in rat models of stroke, seizures and sensorimotor gating deficit

British Journal of Pharmacology

Volumn 158, Issue 8, 2009, Pages 2005-2013

  Cao, W ^a   Shah, H P ^a   Glushakov, A V ^a   Mecca, A P ^b   Shi, P ^b   Sumners, C ^b   Seubert, C N ^a   Martynyuk, A E ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Glutamate; Prepulse inhibition; Seizures; Sensorimotor gating; Stroke

Indexed keywords

3,5 DIBROMO LEVO PHENYLALANINE; DIZOCILPINE; ENDOTHELIN 1; PENTETRAZOLE; PHENYLALANINE DERIVATIVE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTERIAL PRESSURE; ARTICLE; BRAIN DISEASE; BRAIN INJURY; CONTROLLED STUDY; DRUG EFFICACY; HEART RATE; HYPEREKPLEXIA; INJECTION; MALE; MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SEIZURE; SENSORIMOTOR GATING DEFICIT; STROKE; SYMPTOM; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; ENDOTHELIN-1; GAIT DISORDERS, NEUROLOGIC; GLUTAMIC ACID; MALE; PENTYLENETETRAZOLE; PHENYLALANINE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; STARTLE REACTION; STROKE;

EID: 71649087602     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00498.x     Document Type: Article

References (40)

1. Abekawa T, Ito K, Koyama T (2006). Role of the simultaneous enhancement of NMDA and dopamine D(1) receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 374: 177 193.
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2 S1 S209.
3. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A et al. (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57: 270 276.
4. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H (1986). Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17: 472 476.
5. Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234 258.
6. Braun I, Genius J, Grunze H, Bender A, Möller HJ, Rujescu D (2007). Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr Res 97: 254 263.
7. Brody SA, Geyer MA, Large CH (2003). Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169: 240 246.
8. Carreño M, Donaire A, Sánchez-Carpintero R (2008). Cognitive disorders associated with epilepsy: diagnosis and treatment. Neurologist 14: S26 34.
9. Cascella NG, Schretlen DJ, Sawa A (2009). Schizophrenia and epilepsy: is there a shared susceptibility? Neurosci Res 63: 227 235.
10. During MJ, Spencer DD (1993). Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 341: 1607 1610.
11. Eyjolfsson EM, Brenner E, Kondziella D, Sonnewald U (2006). Repeated injection of MK-801: an animal model of schizophrenia? Neurochem Int 48: 541 546.
12. Ferro JM, Pinto F (2004). Poststroke epilepsy: epidemiology, pathophysiology and management. Drugs Aging 21: 639 653.
13. Finley Caulfield A, Wijman CA (2008). Management of acute ischemic stroke. Neurol Clin 26: 345 371.
14. Garcia JH, Wagner S, Liu KF, Hu XJ (1995). Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. statistical validation. Stroke 26: 627 634.
15. Geyer MA, Dulawa SC (2003). Assessment of murine startle reactivity, prepulse inhibition, and habituation. Curr Protoc Neurosci Nov; Chapter 8: Unit 8.17.
16. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156: 117 154.
17. Gonzalez CL, Kolb B (2003). A comparison of different models of stroke on behaviour and brain morphology. Eur J Neurosci 18: 1950 1962.
18. Idris NF, Repeto P, Neill JC, Large CH (2005). Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 179: 336 348.
19. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301 1308.
20. Jorge RE, Robinson RG, Arndt S, Starkstein S (2003). Mortality and post-stroke depression: a placebo controlled trial of antidepressants. Am J Psychiatry 160: 1823 1829.
21. Kemp JA, McKernan RM (2002). NMDA receptor pathways as drug targets. Nat Neurosci 5: 1039 1042.
22. Large CH, Webster EL, Goff DC (2005). The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 181: 415 436.
23. Li H, Gao Y, Freire CD, Raizada MK, Toney GM, Sumners C (2006). Macrophage migration inhibitory factor in the PVN attenuates the central pressor and dipsogenic actions of angiotensin II. FASEB J 20: 1748 1750.
24. Mattson MP (2008). Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann NY Acad Sci 1144: 97 112.
25. Mecca AP, O'Connor TE, Katovich MJ, Sumners C (2009). Candesartan pre-treatment is cerebroprotective in a rat model of endothelin-1 induced middle cerebral artery occlusion. Exp Physiol 94: 937 946.
26. Mehta SL, Manhas N, Raghubir R (2007). Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 54: 34 66.
27. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Neuroscience 17: 2921 2927.
28. Moyanova SG, Kortenska LV, Mitreva RG, Pashova VD, Ngomba RT, Nicoletti F (2007). Multimodal assessment of neuroprotection applied to the use of MK-801 in the endothelin-1 model of transient focal brain ischemia. Brain Res 1153: 58 67.
29. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998 1007.
30. Pringle AK, Schmidt W, Deans JK, Wulfert E, Reymann KG, Sundstrom LE (2003). 7-Hydroxylated epiandrosterone (7-OH-EPIA) reduces ischaemia-induced neuronal damage both in vivo and in vitro. Eur J Neurosci 18: 117 124.
31. Rasmussen BA, O'Neil J, Manaye KF, Perry DC, Tizabi Y (2007). Long-term effects of developmental PCP administration on sensorimotor gating in male and female rats. Psychopharmacology (Berl) 190: 43 49.
32. Razoux F, Garcia R, Lena I (2007). Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens. Neuropsychopharmacology 32: 719 727.
33. Rung JP, Carlsson A, Ryden Markinhuhta K, Carlsson ML (2005). (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29: 827 832.
34. Sharkey J, Ritchie IM, Kelly PA (1993). Perivascular microapplication of endothelin-1: a new model of focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 13: 865 871.
35. Takeda Y, Inoue Y, Tottori T, Mihara T (2001). Acute psychosis during intracranial EEG monitoring: close relationship between psychotic symptoms and discharges in amygdala. Epilepsia 42: 719 724.
36. Tejkalová H, Kaiser M, Klaschka J, Stastný F (2007). Does neonatal brain ischemia induce schizophrenia-like behavior in young adult rats? Physiol Res 56: 815 823.
37. Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Davis J, Pinna G et al. (2005). Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 57: 500 509.
38. Umegaki M, Sanada Y, Waerzeggers Y, Rosner G, Yoshimine T, Heiss WD et al. (2005). Peri-infarct depolarizations reveal penumbra-like conditions in striatum. J Neurosci 25: 1387 1394.
39. Wolf ME, Xue CJ, Li Y, Wavak D (2000). Amphetamine increases glutamate efflux in the rat ventral tegmental area by a mechanism involving glutamate transporters and reactive oxygen species. J Neurochem 75: 1634 1644.
40. Yarotskyy V, Glushakov AV, Sumners C, Gravenstein N, Dennis DM, Seubert CN et al. (2005). Differential modulation of glutamatergic transmission by 3,5-dibromo-L-phenylalanine. Mol Pharmacol 67: 1648 1654.